SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML

Clin Lymphoma Myeloma Leuk. 2018 Dec;18(12):769-772. doi: 10.1016/j.clml.2018.10.007. Epub 2018 Oct 21.

Abstract

Mutations in isocitrate dehydrogenase isoform (IDH) 1 and 2 occur in approximately 25% of patients with acute myeloid leukemia (AML). These mutations lead to a block in myeloid differentiation and ultimately, to the development of AML. Inhibitors of mutant IDH1 and 2 have recently been approved by the US Food and Drug Administration and their use has led to clinical responses with prolonged duration of response. IDH inhibitors in combination with standard-of-care therapy and other small molecular inhibitors are now being used.

Keywords: Acute myeloid leukemia; Beta-hydroxyglutarate; Enasidenib; Isocitrate dehydrogenase; Ivosidenib.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers
  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / therapeutic use
  • Humans
  • Isocitrate Dehydrogenase / genetics
  • Isocitrate Dehydrogenase / metabolism*
  • Isoenzymes
  • Leukemia, Myeloid, Acute / diagnosis
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / etiology
  • Leukemia, Myeloid, Acute / metabolism*
  • Molecular Targeted Therapy
  • Mutation
  • Protein Processing, Post-Translational
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Biomarkers
  • Enzyme Inhibitors
  • Isoenzymes
  • Isocitrate Dehydrogenase